Alzheimer’s

Brain physiology
#Alzheimer's #Biomarkers #Neurodegenerative disorders #Parkinson's #Proteomics

Uncovering biomarkers of ageing and neurodegenerative disease

The Global Neurodegeneration Proteomics Consortium (GNPC) has released research analyses of one of the world’s largest protein datasets in order offer new insights into the biological underpinnings of major neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s disease. The findings, published in a series of papers in Nature Medicine, reveal… Read More

#News

#Alzheimer's #Gene therapy #Neuroscience #Voyager Therapeutics

Voyager adds fourth Alzheimer’s disease programme to pipeline

Voyager Therapeutics has added a new programme that modulates the expression of apolipoprotein E (APOE), the strongest genetic risk factor for Alzheimer’s disease (AD).  The programme uses a proprietary intravenous (IV)-delivered, blood-brain barrier (BBB)-penetrant TRACER capsid to deliver a bifunctional payload that is designed to decrease expression… Read More

#News

#Alzheimer's #Association of the British Pharmaceutical Industry #National Institute for Health and Care Excellence (NICE) #UK

From the Editor: Not NICE enough

The recent decision by the National Institute of Health and Care Excellence (NICE) to reject two Alzheimer’s drugs on the basis of “not providing good value for money” was met with considerable disappointment.  Pharmaceutical company Eisai, developer of the rejected therapy lecanemab, was understandably disappointed , saying it was… Read More

#Exclusive Content

Neurons
#Alzheimer's #Collaboration #Enhanced Genomics #Genetics / genomics #Multi-omics #Neuroscience #University of Cambridge

Genomics partnership discovers novel targets for Alzheimer’s

Biotechnology company Enhanced Genomics has announced a strategic partnership with The ALBORADA Drug Discovery Institute at the University of Cambridge.   Funded by Alzheimer’s Research UK, The ALBORADA Drug Discovery Institute is developing the next generation of treatments for the diseases that cause dementia.   The partnership… Read More

#News

#Alzheimer's #Cellular imaging #Drug discovery #Imaging #Japan #Nanobodies #Neuroscience

Nanobody-based 3D imaging boosts neuroscience research

Scientists have created a nanobody-based method that enables ultra-fast, high-resolution 3D mapping of neurons and glia in thick brain tissues.  The researchers from Japan have developed a fast, high-sensitivity three dimensional immunohistochemistry (3D-IHC) method using nanobodies fused with peroxidase and a novel signal amplification system.  … Read More

#News

Neurons in a brain with Alzheimer's disease
#Alzheimer's #Eisai #National Institute for Health and Care Excellence (NICE) #Neuroscience

NICE rejects Alzheimer’s drugs for lack of cost-effectiveness

The UK National Institute for Health and Care Excellence (NICE) has reached its final decision on two Alzheimer’s treatments, denying their use on the NHS due to the therapies not providing “good value for money.”  Eli Lilly’s donanemab and Eisai’s lecanemab were under final draft guidance by… Read More

#News #Regulatory #Trending News

#AI / data analytics / healthtech / informatics #Alzheimer's #CNS #Gene editing #Human disease models #Interview #Neurodegenerative disorders #Neurology #Neuropsychiatric disorders #Neuroscience #Precision medicine #PrecisionLife #Stem cells

Podcast: Unlocking neuroscience drug discovery

This is the latest episode of the free DDW narrated podcast, titled “Innovative uses for biomarkers in drug discovery”, which covers three articles written for DDW Volume 24 – Issue 4, Fall 2023. They are called: “Advances in neuroscience drug discovery”, “Putting human data at the centre of… Read More

#News

Neurones in the brain
#Alzheimer's #Cell and gene therapy #Cognitive impairment #Gene therapy #Neurology #Neuroscience #University of California San Diego

Alzheimer’s gene therapy shows promise in preserving brain function

Researchers at University of California San Diego School of Medicine have developed a gene therapy for Alzheimer’s disease (AD) that could help protect the brain from damage and preserve cognitive function. Unlike existing treatments for AD that target unhealthy protein deposits in the brain, the new approach could help address… Read More

#News

#Alzheimer's #Mergers and acquisitions #Neurodegenerative disorders #Neurology #Neuroscience #Sanofi

Sanofi expands neurology pipeline with Vigil Neuroscience acquisition

Sanofi has entered into an agreement to acquire Vigil Neuroscience, a clinical-stage biotechnology company focused on developing novel therapies for neurodegenerative diseases, for $470 million.  The company says this acquisition in neurology, one of Sanofi’s four strategic disease areas, enhances its early-stage pipeline and includes VG-3927, which… Read More

#Business & Investment #News #Trending News

Neurons in the brain
#Alta Neuroscience #Alzheimer's #Biomarkers #Blood-based biomarkers #Diagnostics #Roche

How Roche is advancing Alzheimer’s research

DDW’s Megan Thomas speaks with Dr Maria-Magdalena Patru, Scientific Partner at Roche Diagnostics US, about how advances in Alzheimer’s disease (AD), particularly blood-based biomarkers (BBM), can enable earlier, more accurate, and accessible detection of the disease, supporting timely treatment and improved patient outcomes.  MT: Why is improving AD diagnostics crucial… Read More

#Exclusive Content

Gold compound
#Alzheimer's #BioInnovation Institute #Biotech hubs #Cognition Therapeutics #India #Interview #Market reporting #Neurodegenerative disorders #Neuroscience #Pregnancy #Start-ups #Women's health

Podcast: Where are scientists making waves in drug discovery?

This is the latest episode of the free DDW narrated podcast, titled “Where are scientists making waves in drug discovery?”, which covers three articles written for DDW Volume 24 – Issue 3, Summer 2023. They are called: “How pharma is targeting advances in Alzheimer’s treatments”, “The start-up disrupting… Read More

#News

Lecanemab
#Alzheimer's #Biogen #Eisai #European Commission #Monoclonal antibodies #Neuroscience

Lecanemab gets EU approval in early Alzheimer’s

The European Commission (EC) has granted Leqembi (lecanemab) Marketing Authorisation (MA) in the European Union (EU).  The approval makes the medicine the first therapy that targets an underlying cause of Alzheimer’s disease (AD) to be granted a MA in the EU.  Lecanemab is indicated for… Read More

#News #Regulatory #Trending News

Neurons in a brain with Alzheimer's disease
#Alzheimer's #Dementia #Therapeutic Antibodies #UK Dementia Research Institute

Scientists discover why Alzheimer’s drugs are effective

Scientists in the UK and Belgium have discovered new insights into how four different anti-amyloid drugs interact with amyloid beta protein, revealing why the drugs have had varying levels of success at treating Alzheimer’s disease. Amyloid beta is one of the toxic proteins which builds up in clumps… Read More

#News #Trending News

Patient holding pill in hand
#Alzheimer's #Neuroscience #Phase III trial #Tau protein #TauRx Pharmaceutics

Oral treatment could slow progress of Alzheimer’s disease

Researchers have reported a potential oral treatment for Alzheimer’s disease (AD) that slowed its progression over a period of at least 18 months.  Developed by Singaporean company TauRx Pharmaceutics, the scientists based in Aberdeen, UK, report that hydromethylthionine mesylate (HMTM) could be the first oral treatment for… Read More

#News

#Alzheimer's #Antibody drug conjugate (ADC) #hepatitis #Monoclonal antibodies #Oncology #Therapeutic Antibodies

This week in drug discovery (31 March – 4 April) 

News round-up for 31 March – 4 April by DDW Senior Digital Content Editor Diana Spencer. The headlines this week have demonstrated the importance of antibody therapies, particularly in treating cancer, but also as potential therapeutics for a range of other diseases including hepatitis D and Alzheimer’s. Read More

#News

Neurons in a brain with Alzheimer's disease
#Alzheimer's #Antibody #Gene therapy #Neuroscience #Tau protein #Voyager Therapeutics

Anti-tau antibody and gene therapy show potential in Alzheimer’s

A single IV administration of tau silencing gene therapy VY1706 significantly reduced tau mRNA and protein levels, with broad brain distribution and liver de-targeting, in preclinical studies.  Voyager Therapeutics will share the new data from its two preclinical programmes for Alzheimer’s disease (AD) at the 2025 International… Read More

#News